We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
-5.05%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$126M
AUM Growth
-$52.8M
Cap. Flow
+$7.71M
Cap. Flow %
6.14%
Top 10 Hldgs %
48.85%
Holding
64
New
14
Increased
25
Reduced
1
Closed
7

Top Buys

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$1.83M
2
TSRO
TESARO, Inc.
TSRO
+$1.26M
3
CLVS
Clovis Oncology, Inc.
CLVS
+$1.06M
4
BMY icon
Bristol-Myers Squibb
BMY
+$783K
5
SCTL
Societal CDMO, Inc. Common Stock
SCTL
+$305K

Top Sells

Rank Stock Value
1
SDS icon
ProShares UltraShort S&P500
SDS
+$656K
2
CPHD
Cepheid Inc
CPHD
+$315K
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$311K
4
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$208K
5
NVAX icon
Novavax
NVAX
+$54K

Sector Composition

Rank Sector Weight
1 Healthcare 65.26%
2 Miscellaneous 34.09%
3 Real Estate 0.65%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XBI icon
1
CALL
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$17.8M 14.15%
+300,000
New +$18.5M
XBI icon
2
State Street SPDR S&P Biotech ETF
XBI
$11.7B
$7.7M 6.13%
130,000
– –
IBB icon
3
iShares Biotechnology ETF
IBB
$10.8B
$6.63M 5.29%
75,000
– –
BMY icon
4
Bristol-Myers Squibb
BMY
$137B
$5.26M 4.19%
90,000
+14,314
+19% +$783K
MRK icon
5
Merck
MRK
$369B
$4.93M 3.93%
87,718
– –
ALKS icon
6
Alkermes
ALKS
$8.2B
$4.57M 3.64%
82,296
+619
+0.8% +$33.1K
IONS icon
7
Ionis Pharmaceuticals
IONS
$10.4B
$3.71M 2.95%
77,550
+1,111
+1% +$44K
PFE icon
8
Pfizer
PFE
$160B
$3.65M 2.91%
118,364
– –
SGEN
9
DELISTED
Seagen Inc. Common Stock
SGEN
$3.6M 2.87%
68,310
+357
+0.5% +$21.5K
INCY icon
10
Incyte
INCY
$25.9B
$3.51M 2.8%
35,031
+405
+1% +$39.5K
BIB icon
11
ProShares Ultra NASDAQ Biotechnology
BIB
$105M
$3.39M 2.7%
85,000
– –
ALNY icon
12
Alnylam Pharmaceuticals
ALNY
$31.7B
$3.32M 2.65%
88,784
+43,720
+97% +$1.83M
AZN icon
13
AstraZeneca
AZN
$255B
$3.28M 2.61%
60,000
– –
CELG
14
DELISTED
Celgene Corp
CELG
$3.16M 2.52%
27,286
+427
+2% +$47.6K
QGENF
15
DELISTED
QIAGEN NV
QGENF
$3.13M 2.49%
111,683
+1,118
+1% +$31.3K
BIIB icon
16
Biogen
BIIB
$32.7B
$3.08M 2.46%
10,872
+168
+2% +$49.8K
ALXN
17
DELISTED
Alexion Pharmaceuticals
ALXN
$3.06M 2.43%
24,973
+402
+2% +$49.2K
MTD icon
18
Mettler-Toledo International
MTD
$28.2B
$3.01M 2.4%
7,188
– –
REGN icon
19
Regeneron Pharmaceuticals
REGN
$83.2B
$2.82M 2.25%
7,684
+172
+2% +$65.4K
AMGN icon
20
Amgen
AMGN
$236B
$2.74M 2.18%
18,743
+421
+2% +$63.4K
BMY icon
21
CALL
Bristol-Myers Squibb
BMY
$137B
$2.63M 2.1%
45,000
– –
BMRN icon
22
BioMarin Pharmaceuticals
BMRN
$12.6B
$2.62M 2.08%
31,579
+940
+3% +$80.8K
VRTX icon
23
Vertex Pharmaceuticals
VRTX
$139B
$2.46M 1.96%
33,357
+1,216
+4% +$98.9K
ILMN icon
24
Illumina
ILMN
$34.4B
$2.43M 1.94%
19,498
+583
+3% +$78.6K
AGIO icon
25
Agios Pharmaceuticals
AGIO
$2.05B
$2.32M 1.85%
55,524
+832
+2% +$43.7K
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2016 Portfolio in Review

As of Q4 2016, Opus Point Partners Management held 64 positions worth $126M, down 30% from $178M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Opus Point Partners Management deployed $7.71M of net new capital in Q4 2016, opening 14 new positions and adding to 25 existing holdings. Its largest new stake was TESARO, Inc.: 10,000 shares worth $1.34M.

By sector, the portfolio is most concentrated in Healthcare at 65% of assets, up from 44% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Direxion Daily S&P Biotech Bull 3X ETF, an estimated $12.8K trimmed.

  • Opus Point Partners Management's largest Q4 2016 buy was TESARO, Inc.: 10,000 shares worth $1.34M.
  • Opus Point Partners Management added most to Alnylam Pharmaceuticals in Q4 2016, an estimated $1.83M increase.
  • Opus Point Partners Management's biggest Q4 2016 reduction was Direxion Daily S&P Biotech Bull 3X ETF, cutting an estimated $12.8K.
  • Opus Point Partners Management fully exited ProShares UltraShort S&P500 in Q4 2016, selling an estimated $656K.
  • Opus Point Partners Management's ten largest holdings make up 49% of its $126M portfolio in Q4 2016.
  • Opus Point Partners Management opened 14 new positions and closed 7 in Q4 2016.
  • Opus Point Partners Management's portfolio value fell 30% quarter-over-quarter to $126M.

Based on Opus Point Partners Management's 13F filing for Q4 2016, filed 14 Feb 2017.